Esprinet releases H1 2026 investor presentation showing gross sales rise 8% to € 2.1 billion

• Esprinet investor presentation covered H1 2026, showing gross sales up 8% year-on-year to EUR 2.1 billion.
• Sales from contracts with customers rose 8% to EUR 2.1 billion; gross profit increased 9% to EUR 121 million.
• Adjusted EBITDA climbed 27% to EUR 31.9 million; margin improved to 1.53% from 1.3%.
• Net income rose 40% to EUR 4.8 million; Q2 net income fell 34% to EUR 1.9 million.
• Net financial position was negative EUR 325.5 million; cash conversion cycle ended at 25 days; ROCE was 6.3%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esprinet S.p.A. published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.